sophie piperno-neumann
机构: institut Curie
每年引用次数
引用次数
引用: 19,035
H-指数: 66
I10-指数 : 173
出版物: 421
Etopophos® : données cliniques et modalités pratiques d'utilisation
S. Piperno-Neumann
La Lettre du cancérologue 6 ( 2) 7 -9
1997
Le mélanome de la choroïde : revue de la littérature
L. Desjardins , L. Bengrine-Lefevre , S. Piperno-Neumann
La Lettre du cancérologue 15 ( 1) 20 -28
2006
Actualités 1999 dans la prise en charge des sarcomes
S. Piperno-Neumann
La Lettre du cancérologue 8 ( 6) 230 -231
1999
Chimiothérapie du cancer de l'ovaire : actualités sur Caelyx® en 2003-2004 et perspectives
A. C. Hardy-Bessard , T. Petit , I. Ray-Coquard , K. Djazouli
La Lettre du cancérologue 13 ( 5) 203 -209
2004
L'évaluation de la qualité de vie en oncologie : peut-on quantifier la qualité ?
L. Batel-Copel , S. Piperno-Neumann
La Lettre du cancérologue 6 ( 1) 17 -20
1997
DEDIFFERENTIATED CHONDROSARCOMA: RETROSPECTIVE ANALYSIS OF 15 CASES. NATURAL HISTORY AND THERAPEUTIC STRATEGY
S. Piperno-Neumann , P. Pouillart , B. Tomeno , L. Ollivier
Orthopaedic Proceedings 58 -58
2002
IS INTERILIOABDOMINAL DISARTICULATION STILL WARRANTED IN 2001
S. Piperno-Neumann , A. Babinet , G. de Guetz , Ph. Anract
Orthopaedic Proceedings 59 -59
2002
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
N. Bouvet , A. Fraslin , A. Fraslin , S. Piperno-Neumann
Annals of Oncology
2021
Predicting metastasis in uveal melanoma: Identification of a prognostic classifier by genomic profiling using array-CGH of 78 ocular tumors (OT) and 66 liver metastases (LM)
J. Couturier , J. Trolet , P. Hupe , L. Desjardins
Journal of Clinical Oncology 26 ( 15_suppl) 9041 -9041
2008
Angiosarcomas: Natural history and prognostic factors from 161 cases in three French institutions
A. Le Cesne , C. Robert , S. Bonvalot , D. Ranchère
Journal of Clinical Oncology 23 9024 -9024
1
2005
Final results of a FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS)
P. Pautier , B. Bui Nguyen , N. Penel , S. Piperno-Neumann
Journal of Clinical Oncology 27 10527 -10527
16
2009
A retrospective study of parameters influencing survival after surgical resection of lung metastases of bone and soft tissue sarcomas
S. Piperno-Neumann , K. Homicsko , S. Mussot , P. Anract
Journal of Clinical Oncology 27 10541 -10541
2009
Prospective study of surveillance testing for metastasis in 100 high-risk uveal melanoma patients.
S. Piperno-Neumann , V. Servois , P. Mariani , C. Plancher
Journal Francais D Ophtalmologie 38 ( 6) 526 -534
13
2015
NA17 and MAGE gene expression in 20 adult sarcoma tumors: Retrospective analysis by semi-quantitative RT-PCR
S. Piperno-Neumann , O. Lantz , G. De Pinieux , V. Laurence
Journal of Clinical Oncology 22 9053 -9053
2004
Effect of adjuvant radiotherapy on survival in localized limb or trunk wall well-differentiated liposarcoma (WDLPS).
A. Duret , E. Stoeckle , S. Bonvalot , A. Italiano
Journal of Clinical Oncology 28 10079 -10079
1
2010
A national registry for the off-label use of targeted therapies in patients (pts) with malignant mesenchymal tumors: A retrospective study from the GSF-GETO.
J. Bay , A. Le Cesne , A. Cioffi , N. Penel
Journal of Clinical Oncology 28 10097 -10097
1
2010
Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
J. Khalifa , M. Ouali , L. Chaltiel , S. Le Guellec
BMC Cancer 15 ( 1) 700 -700
26
2015
016 Identification d’une signature génomique de haut risque métastatique du mélanome uvéal
L. Desjardins , J. Trolet , P. Hupe , I. Labigot
Journal Français d'Ophtalmologie 31 21 -21
2008
277 Preclinical antitumor assessment of bendamustine in human primary uveal melanoma xenografts
F. Némati , S. Piperno-Neumann , L. Desjardins , N. Karboul
Ejc Supplements 8 ( 7) 90
2010
1636P METASYN: Patterns of care and outcomes of 387 METAstatic SYNovial sarcoma: Real-life data from the French Sarcoma Group (GSF/GETO)
C. Moreau-Bachelard , M. Toulmonde , A. Le Cesne , M. Brahmi
Annals of Oncology 31
2020